Marina Kaplan v. Advanz Pharma Corp., Pinnacle Biologics, Inc., and Concordia Pharmaceuticals, Inc.

CourtDistrict Court, N.D. Ohio
DecidedJune 23, 2026
Docket1:24-cv-01500
StatusUnknown

This text of Marina Kaplan v. Advanz Pharma Corp., Pinnacle Biologics, Inc., and Concordia Pharmaceuticals, Inc. (Marina Kaplan v. Advanz Pharma Corp., Pinnacle Biologics, Inc., and Concordia Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Marina Kaplan v. Advanz Pharma Corp., Pinnacle Biologics, Inc., and Concordia Pharmaceuticals, Inc., (N.D. Ohio 2026).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO

Marina Kaplan, Case No. 1:24-cv-01500-PAB

Plaintiff,

-vs- JUDGE PAMELA A. BARKER

Advanz Pharma Corp., et al.,

Defendants. MEMORANDUM OPINION & ORDER

Currently pending before the Court is Defendants Advanz Pharma Corp. (“Advanz”), Pinnacle Biologics, Inc. (“Pinnacle”), and Concordia Pharmaceuticals, Inc.’s (“Concordia”) Motion for Summary Judgment (“Defendants’ Motion”). (Doc. No. 34.) Plaintiff Marina Kaplan (“Kaplan”) filed her Opposition on January 19, 2026, to which Defendants replied on February 2, 2026. (Doc. Nos. 38, 40.) On February 2, 2026, Defendants also filed a Motion to Strike the Declaration of Milan Dubravka (the “Motion to Strike”). (Doc. No. 41.) Kaplan filed her Opposition to the Motion to Strike on February 15, 2026, to which Defendants replied on February 22, 2026. (Doc. Nos. 42, 43.) For the reasons set forth below, the Court rules as follows. The Motion to Strike is granted in part and denied in part as follows. The Court strikes Paragraph 30 of Dubravka’s Declaration and denies the Motion to Strike in all other respects. Defendants’ Motion is granted in part and denied in part as follows. The Court grants summary judgment in favor of Concordia on all of Plaintiff’s claims against it. The Court grants summary judgment in favor of Advanz and Pinnacle on Plaintiff’s sex discrimination claims and wrongful discharge claim. The Court denies summary judgment in favor of Advanz and Pinnacle on Plaintiff’s age discrimination claims and national origin/religious discrimination claims. I. Factual Background Kaplan is a female, who was born in 1962, and is of Ukrainian and Jewish descent. (Doc. No. 23, ¶¶ 13–14.) On January 16, 2023, Kaplan began her employment with Defendants as a RBM (e.g. a salesperson). (Kaplan Dep. 96:23–97:1.) When Kaplan started her employment, she reported to Milan Dubravka (“Dubravka”). (Id. at 101:2–11.) Dubravka, in turn, reported to Larry Miles (“Miles”), the general manager of Pinnacle. (Doc. No. 38-10, ¶ 4.) Kaplan was assigned to the “Pittsburgh” territory. (Dubravka Dep. 130:21–132:9.)

A. Kaplan is responsible for selling PHOTOFRIN® and receives training on her role with Defendants RBMs are responsible for the sale of PHOTOFRIN® to physicians and hospitals. PHOTOFRIN® is a photosensitizing agent, and it is used in tandem with Photodynamic Light Therapy (“PDT”) to treat certain cancers. (Dubravka Dep. 121:25–124:1.) Physicians typically administer PDT treatments in three separate illuminations, usually occurring over a two- to three-day period. (Dubravka Dep. 169:20–170:7.) RBMs were also responsible for educating physicians and their staff about procedure. (Dubravka Dep. 21:23–22:7.) In addition to education, RBMs participate in the PDT procedure by calibrating the laser for the physician. (Kaplan Dep. 99:18–22; Dubravka Dep. 123:9–13, 212:15–23.) As part of the onboarding process, Kaplan received training on these aspects of her job. Dubravka provided one-on-one training to Plaintiff and Plaintiff attended the PHOTOFRIN® with PDT training from January 24 to January 27, 2023. (Dubravka Dep. 155:13–158:2; Kaplan Dep. 102:12-103:3, 104:10-17.) She also observed Dubravka perform PDT illuminations at the University of Illinois. (Dubravka Dep. 162:22-165:14, 169:10-170:20.) After the formal training ended, Plaintiff continued to observe Dubravka perform PDT illuminations in the field. (Kaplan Dep.

2 147:24–148:24.) B. Kaplan has some issues with her first cases On March 3, 2023, Kaplan attended her first independent PDT procedure at Virginia Commonwealth University (“VCU”). (Kaplan Dep. 448:12–450:22, 455:20–25.) Kaplan struggled with her first procedure, and facetimed Dubravka to obtain his assistance with the procedure. (Id. at 204:22–207:13, 211:2–9.) After the procedure, the attending doctor, Dr. Shepherd, emailed Dubravka concerning his dissatisfaction with Kaplan:

. . . our team is very disappointed in the support we had for the case and this was an extremely frustrating experience for all of us involved. Clearly she was not adequately trained or prepared and basic issues could not be dealt with. This was the worst industry support I have experienced in 20 years of dozens of procedural technologies. It was unacceptable and could have affected patient safety. Your company knows that it should send an experienced support staff to a new site or site that has not done this procedure in a long time. There were other issues as well . . . but those were minor compared to the actual procedure support.

(Doc. No. 39-2, PageID #2521.) Dubravka responded that he agreed that Kaplan was “not experienced enough to support your case” and “[t]he plan was that I would assist her, but unfortunately the timing of your case conflicted with PDT Academy I ran yesterday in Montana.” (Id. at PageID #2519–20.) Dubravka believes that “[t]he difficulty during this case was not attributable to Ms. Kaplan or her abilities.” (Doc. No. 38-10 at ¶ 21.) Based on communications with Dr. Shepherd, Dubravka believes that “[n]othing Ms. Kaplan did or said created any compliance issue that was reported to the Company.” (Id.) And Dr. Shepherd “did not report to [him] anything about Ms. Kaplan’s attitude . . . , safety violations, or being banned from VCU.” (Id.) A week after the VCU case, Durbavka sent an email criticizing Kaplan for the way she handled certain communications with another client (UPMC): 3 OK, so you sent the email, fain (sic).

But that’s not where your job ends, do you understand that, Marina?

Do you understand that you actually chase the answer down until you know. Until you know for certain they have/have not the kits. Get a phone number, call her, confirm, send a follow up email, go down there in person, whatever it takes. AT THE END OF THE DAY IT IS YOUR RESPONISBILITY THAT EVERYTHING IS READY FOR THESE CASES.

FOR A SECOND DON’T YOU PUT ANY RESPONSIBILITY ON ALLYSON OR ANY OTHER CLINICAL SUPPORT TECH BECAUSE ITS NOT THEIR JOB! BY THE WAY, AFTER THIS HICCUP (SIC), WE HAVE SOME FIXING TO DO. I NEED YOU TO BE IN THE CASE NEXT WEEK. ALL ILLUMINATION SESSIONS. I NEED YOU TO MEET WITH DR AWAIS, I| NEED YOU TO MEET HIS TEAM. VICTORIA, MARIE (who saved us today), INFUSION TEAM, ALL OF THEM. IF YOU HAVE THE KITS, BRING SOME WITH YOU.

Part of the problem is you didn’t establish any relationship with the team, they don’t know who you are. This is why the communication is broken, and this is why we didn’t address and handle the kits shortage situation timely.

(Doc. No. 35-16, PageID #848.) This was not the only criticism that Dubravka gave to Kaplan about her work at UPMC. Months later, in October 2023, Dubravka again emailed Kaplan explaining his dissatisfaction with how she had communicated with UPMC: Do me a favor please: Never ever again go to a doctor and be an inconvenience to him/her by asking to reschedule a case. Moving forward, if you have a legitimate reason NOT TO BE IN A CASE ON A WEEKDAY, you go either to me or Jacque and request a case coverage. It is me or Jacque who will make sure to send someone there to cover your case. It’s only when we COLLECTIVELY cannot find coverage for you that you would go to the doctor to see if there is a chance to reschedule it.

* * *

Marina, I need you to understand one thing. As a NSM, I will do anything to keep my number 1 account in good standings (sic). This means I will not hesitate for a second to take that account away from you and assign it someone else, if you cannot accommodate/service that account.

4 (Doc. No. 35-18, PageID #859–60.) C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Texas Department of Community Affairs v. Burdine
450 U.S. 248 (Supreme Court, 1981)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
St. Mary's Honor Center v. Hicks
509 U.S. 502 (Supreme Court, 1993)
O'CONNOR v. Consolidated Coin Caterers Corp.
517 U.S. 308 (Supreme Court, 1996)
Gross v. FBL Financial Services, Inc.
557 U.S. 167 (Supreme Court, 2009)
Stansberry v. Air Wisconsin Airlines Corp.
651 F.3d 482 (Sixth Circuit, 2011)
William Sanford v. Main Street Baptist Church Manor
449 F. App'x 488 (Sixth Circuit, 2011)
Provenzano v. LCI Holdings, Inc.
663 F.3d 806 (Sixth Circuit, 2011)
George A. Darnell v. Target Stores
16 F.3d 174 (Seventh Circuit, 1994)
Donald G. Wexler v. White's Fine Furniture, Inc.
317 F.3d 564 (Sixth Circuit, 2003)
Stephen B. Himmel v. Ford Motor Company
342 F.3d 593 (Sixth Circuit, 2004)
Jon Jermer v. Siemens Energy & Automation, Inc.
395 F.3d 655 (Sixth Circuit, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
Marina Kaplan v. Advanz Pharma Corp., Pinnacle Biologics, Inc., and Concordia Pharmaceuticals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/marina-kaplan-v-advanz-pharma-corp-pinnacle-biologics-inc-and-ohnd-2026.